Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q4 2024 Earnings Presentation
15 slides from Quanterix's earnings presentation, Mar 17, 2025
Slide 1: Fourth Quarter & Full Year 2024 Earnings
„ Fourth Quarter & Full Year 2024 Earnings March 17, 2025
Slide 2: Legal Information
Legal Information IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix (the “Merger”), Quanterix filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, dated February 13, 2025
Slide 3: Legal Information: Forward-Looking Statements
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor prov
Slide 4: Accelerating strategic plan to deliver strong returns
Accelerating strategic plan to deliver strong returns Delivered consistent double-digit revenue growth In a constrained capital spending environment due to a differentiated business model Expanding addressable market with Simoa ONE and Emission Adding $2B immunology opportunity Leading Alzheimer’s D
Slide 5: Extending Simoa to more labs with a growing menu
Extending SIMOA to more labs with a growing menu Differentiated value enabled by ultra-sensitivity 13 markers in Neurology Neurology incl. BD-Tau solution in single and multiplex formats Lucent AD Complete Groundbreaking 4-plex assay N4PD: NfL, GFAP, (Multi-marker: p-Tau217, Aβ42, Aβ40, UCHL-1, AD-s
Slide 6: Simoa ONE: Accelerating our expansion into Immunology & Oncology
Accelerating our expansion into Immunology & Oncology Extends our Up to 01 #1 lead position 10x more sensitive in ultra-sensitivity compared to current SIMOA SIMOA One Enter a Mid-plex 02 capability $2B+ addressable Breaking past immunology segment detection limits set Optically encoded barcodes on
Slide 7: Building a global infrastructure for AD testing
Building a global infrastructure for AD testing PAR T 1 : E N AB L E PAR T N E R S Our Partners Across the Globe ~$20 Million investment over 2024 and 2025 DEM O NST RAT I NG EARLY SUCCESS I N L AB ENABL EM ENT 12 PART NERS TO DAY 4 Prospective studies Brazil China PAR T 2 : O U R L AB China 0.75M T
Slide 8: Quanterix and Akoya: a compelling combination
Quanterix and Akoya: a compelling combination Unlocks a high-growth $5B1 addressable Creates first integrated Transformative research market across Neurology, Immunology platform of liquid and Portfolio tissue biomarkers and Oncology with pipeline to enter an additional $10B2 Diagnostics segment Exp
Slide 9: Review of Q4-24 Results
Review of Q4-24 Results (in millions) Q4 GAAP Q4 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2023 2024 2023 2024 Var % Revenue Mix 9% 49% 25% 17% Revenue 31.5 35.2 31.5 35.2 11% Gross Margin $ 19.4 22.2 17.3 20.3 17% Revenue Q4 2023 Q4 2024 Gross Margin % 61.5% 63.0% 54.7% 57.7% 300 bps -1% O
Slide 10: Review of Full Year 2024 Results
Review of Full Year 2024 Results (in millions) FY GAAP FY Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2023 2024 2023 2024 Var % Revenue Mix 8% 50% 28% 14% Revenue 122.4 137.4 122.4 137.4 12% Gross Margin $ 74.2 83.1 66.1 75.0 13% Gross Margin % 60.7% 60.5% 54.0% 54.6% 60 bps Revenue FY 2023 F
Slide 11: Strong Balance Sheet
Strong Balance Sheet Cash Liquidity1 Burn Allocating resources to strategic investments 2024 $292M $32M Reduced cash burn from core operations Stable Strategic Liquidity to execute recent transactions and future opportunities 2023 $324M $17M 1 Includes Cash, Cash Equivalents, Marketable Securities,
Slide 12: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others INSTRUMENTS PUBLICATIONS BIOMARKERS Placements Cumulative Cumulative # of units placed In millions USD Cumulative 38.0 256 Number of Drug 3,278 559 568 1,035 Trial Projects 538 972 205 2,781 480 876 168
Slide 13: 2025 Guidance
2025 Guidance Full Year Revenue: 2 to 6% growth $140 to $146 million; excludes revenue from Lucent Diagnostics testing. Gross Margin GAAP Gross Margin between 59 to 63% and Adjusted Gross Margin (Non-GAAP) between 53 to 57%. Cash Usage of $55 to 65 million Operations • $35 to $45 million of cash usa
Slide 14: Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) QUANTERIX CORPORATION Reconciliation of Net Loss to Adjusted EBITDA (non-GAAP) and Adjusted EBITDA Margin (non-GAAP) (Unaudited, amounts in thousands except percentages) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net loss S (11,628
Slide 15: Additional Non-GAAP Financial Measures
Additional Non-GAAP Financial Measures 15